-

Henry Schein Announces the Passing of Board Member E. Dianne Rekow

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC) announced the passing today of E. Dianne Rekow, DDS, Ph.D., a member of the Company’s Board of Directors since 2014 and a leader in the development of digital dentistry.

“Dianne was an extraordinary board member and an internationally known authority on aesthetic and restorative dentistry as well as one of the early pioneers in digital dentistry,” said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer, Henry Schein, Inc. “Dianne’s contributions to the Henry Schein board have been many and impactful, including serving as a member of our Strategic Advisory Committee. We will miss her probing spirit, expertise, and comradery.”

Dr. Rekow was also Professor Emeritus and Fellow at King's College London, where she served as Executive Dean of its Dental Institute and Professor of Orthodontics from 2012 through 2016. From 2002 to 2012, Dr. Rekow was a Professor of Orthodontics at New York University (NYU), during which time she was Senior Vice Provost of Engineering Technology at NYU and was Provost of Polytechnic Institute of NYU. She was also a Senior Scholar of the Sante Fe Group, a leading think-tank dedicated to improving life through oral health.

Dr. Rekow was an internationally known authority on the performance of new dental materials, capitalizing on her engineering education. Her teams carried out research into the use of bio-engineered tissue to facilitate bone replacement in individuals disfigured by disease or developmental defects. She held a number of patents in the dental field and is the author of, or contributor to, more than one hundred publications. Dr. Rekow’s career also included serving as President of both the International Association for Dental Research and the American Association of Dental Research. In 2012, she was elected to the Faculty of Dental Surgery of the Royal College of Surgeons in the UK.

About Henry Schein, Inc.

Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 22,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.

Henry Schein operates through a centralized and automated distribution network, with a selection of more than 120,000 branded products and Henry Schein private-brand products in stock, as well as more than 180,000 additional products available as special-order items.

A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 32 countries and territories. The Company's sales reached $12.4 billion in 2021, and have grown at a compound annual rate of approximately 12.5 percent since Henry Schein became a public company in 1995.

For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, and @HenrySchein on Twitter.

Contacts

Media:
Ann Marie Gothard
Vice President, Global Corporate Media Relations
annmarie.gothard@henryschein.com
+1 (631) 390-8169

Henry Schein, Inc.

NASDAQ:HSIC

Release Summary
Henry Schein announces the passing of board member E. Dianne Rekow, DDS, Ph.D.
Release Versions

Contacts

Media:
Ann Marie Gothard
Vice President, Global Corporate Media Relations
annmarie.gothard@henryschein.com
+1 (631) 390-8169

More News From Henry Schein, Inc.

Henry Schein Expands Partnership with vVARDIS

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC) today announced the expansion of its agreement with vVARDIS, which grants the Company exclusive U.S. distribution rights for the drill-free Curodont™ Repair Fluoride Plus (“Curodont”) product across all dental market segments, effective January 1, 2026. The strategic expansion broadens Henry Schein’s previous exclusivity with the Swiss company, which was announced in 2024 for Dental Service Organizations (DSOs). Starting next ye...

Henry Schein to Participate in Upcoming Investor Conference in December

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc., (Nasdaq: HSIC) the world’s largest provider of health care solutions to office-based dental and medical practitioners, announced today that the Company will present at the following investor conference in December: Piper Sandler’s Healthcare Conference at the Lotte New York Palace Hotel, New York, on December 2, 2025, at 9:00 a.m. Eastern time. Henry Schein’s presentations can be heard via live webcast by visiting www.henryschein.com/IRwebcas...

Henry Schein Reports Record Third Quarter 2025 Financial Results and Raises Full Year Non-GAAP EPS Guidance

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the third quarter ended September 27, 2025. “We are pleased with our financial results for the third quarter, with sales growth accelerating in each of our reportable segments including solid market share gains in our distribution businesses as we are once again focused on driving growth n...
Back to Newsroom